DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)

Autor: Mario Boccadoro, Jesús San-Miguel, Kenshi Suzuki, Niels W.C.J. Van De Donk, Gordon Cook, Andrzej Jakubowiak, Deepu Madduri, Salma Afifi, An-Sofie Stevens, Jordan M. Schecter, William Deraedt, Steven Kuppens, Pankaj Mistry, Lida Pacaud, Erika Florendo, Annemiek Broijl, Francesca Gay, Roberto Mina, Leo Rasche, Philippe Moreau, María-Victoria Mateos, Hermann Einsele, Pieter Sonneveld

Publikováno v: Blood. 140:4630-4632

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b20bc7ef1e1dc76983a0b092be9b548
https://doi.org/10.1182/blood-2022-157021

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma

Autor: Catherine D. Williams, Pamela L. Clemens, Andrew Spencer, Meral Beksac, Yael C Cohen, Ming Qi, Peter M. Voorhees, Christoph Heuck, Ajai Chari, Matthew W Jenner, Philippe Moreau, Michele Cavo, Niels W.C.J. van de Donk, Hartmut Goldschmidt, Irwindeep Sandhu, Steven Kuppens, C. Ola Landgren, Jane Estell, Craig C. Hofmeister, Tobias Neff, Rajesh Bandekar

Publikováno v: Landgren, C O, Chari, A, Cohen, Y C, Spencer, A, Voorhees, P, Estell, J A, Sandhu, I, Jenner, M W, Williams, C, Cavo, M, van de Donk, N W C J, Beksac, M, Moreau, P, Goldschmidt, H, Kuppens, S, Bandekar, R, Clemens, P L, Neff, T, Heuck, C, Qi, M & Hofmeister, C C 2020, ' Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma : a randomized, open-label, multicenter, phase 2 study (CENTAURUS) ', Leukemia, vol. 34, no. 7, pp. 1840-1852 . https://doi.org/10.1038/s41375-020-0718-z
Leukemia
Leukemia, 34(7), 1840-1852. Nature Publishing Group

Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURU

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a7432719c5f9d38a656c4ec334643a
https://doi.org/10.1038/s41375-020-0718-z

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Autor: Fevzi Firat Yalniz, Salomon Manier, Lida Bubuteishvili Pacaud, Vania Hungria, Dominik Dytfeld, Jordan M. Schecter, Mounzer Agha, Steven Kuppens, William Deraedt, Maria-Victoria Mateos, Erika Florendo, Agne Taraseviciute-Morris, Saad Z. Usmani, Binod Dhakal, Michel Delforge, Jane Gilbert, Salma Afifi

Publikováno v: Blood. 138:1835-1835

Introduction: For transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM), autologous stem cell transplant (ASCT) is the standard of care treatment (tx). However, ASCT, which includes a standard melphalan conditioning regimen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f67f668b3b27c24cad4edccface1b5ca
https://doi.org/10.1182/blood-2021-146210

Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA

Autor: Ross I. Baker, Steven Kuppens, Ming Qi, Tobias Neff, Meletios A. Dimopoulos, Hartmut Goldschmidt, S. Vincent Rajkumar, Rajesh Bandekar, Peter M. Voorhees

Publikováno v: Journal of Clinical Oncology. 36:TPS8062-TPS8062

TPS8062Background: Current guidelines for SMM recommend active monitoring for progression to symptomatic MM before initiating treatment as standard of care. Earlier treatment may benefit pts with S...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30a23586339bbe45e779f4e3007432d9
https://doi.org/10.1200/jco.2018.36.15_suppl.tps8062

Conformational states of the switch I region of Ha-ras-p21 in hinge residue mutants studied by fluorescence lifetime and fluorescence anisotropy measurements

Autor: Steven Kuppens, Yves Engelborghs, Mario Hellings, Stefan Verheyden, Jan Jordens

Publikováno v: Protein science : a publication of the Protein Society. 12(5)

The hinge residues (Val29 and Ile36) of the switch I region (also known as the effector loop) of the Ha-ras-p21 protein have been mutated to glycines to accelerate the conformational changes typical for the effector loop. In this work, we have studie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c53099f04a5bdd70c0ea044e69100b37
https://pubmed.ncbi.nlm.nih.gov/12717016